Health
ATPCI: Trimetazidine Fizzles for Post-PCI Angina – Medscape
The antianginal was unable to provide added benefit when added to optimal medical therapy, but one expert questions: Was the right population studied?
Adding trimetazidine to optimal medical therapy does not improve outcomes following successful percutaneous coronary intervention (PCI) for stable angina or a nonST-elevated myocardial infarction (MI), results of the ATPCI trial show.
There was no benefit for the composite primary endpoint of cardiac death, hospitalization for cardiac events, or recurrent/persistent angina requiring an addition, switch, or increased dose of antianginal therapies, or requiring coronary angiography (hazard ratio…
-
General23 hours agoHundreds attend justice march for Kaiden Morgan-Johnston in Morwell
-
Noosa News23 hours agoAlleged Gold Coast conman exposed: elderly woman’s life savings vanish in shocking scam
-
Noosa News23 hours agoHow Roosters star Eliza Lopamaua found her way to NRLW
-
Noosa News24 hours agoBack to the Future the Musical’s extraordinary visual effects mean you’ll see the DeLorean fly